For patients with dry syndrome combined with interstitial pneumonia, hormonal drug therapy, immunosuppressant therapy, and nebulized inhalation therapy can be chosen according to the severity of the disease. Dry syndrome combined with interstitial pneumonia is usually less severe than other connective tissue disease-related interstitial lung disease. In patients with <10% lung lesion extent confirmed by high-resolution CT of the chest and no respiratory symptoms, and with pulmonary carbon monoxide diffusion as a percentage of predicted value >65%, close monitoring and evaluation at approximately 6-month intervals are recommended, and aggressive pharmacologic therapy is not required. Patients with severe and rapidly progressing disease may be treated with oral or intravenous glucocorticoids (commonly methylprednisolone) or with the addition of immunosuppressive agents (cyclophosphamide, mertiomacrolide, etc.). Antifibrotic drugs such as pirfenidone and nidaneb, which are used in the treatment of idiopathic pulmonary fibrosis, may also be considered if necessary. In addition, patients with bronchiectasis can be treated with topical inhaled glucocorticosteroids (inhaled budesonide is commonly used) and β2-adrenoceptor agonists (e.g., salbutamol) by nebulized inhalation. Patients with dry syndrome combined with interstitial pneumonitis should be treated under the guidance of specialists, and the appropriate treatment plan should be selected according to the patient’s condition, and the medication should be prescribed by the doctor.